Floatz logo

17 assets in Penile Cancer

Therapeutic assets addressing Penile Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Penile Cancer
Christian HinrichsP2BB (65)
Fludarabine
Penile Cancer
Christian HinrichsP2BB (65)
9-valent human papillomavirus recombinant vaccine
Penile Cancer
Shanghai Bovax Biotechnology Co., Ltd.P3B (60)
Cabozantinib
Penile Cancer
National Cancer Institute (NCI)P2B (60)
e7 tcr-t cells
Penile Cancer
Christian HinrichsP2B (60)
Ipilimumab
Penile Cancer
National Cancer Institute (NCI)P2B (58)
Nivolumab
Penile Cancer
National Cancer Institute (NCI)P2B (58)
Pembrolizumab
Penile Cancer
UNICANCERP2B (57)
Ivocizumab
Penile Cancer
Fudan UniversityP2CCC (53)
Entinostat
Penile Cancer
National Cancer Institute (NCI)P1/2CC (45)
pds01adc
Penile Cancer
National Cancer Institute (NCI)P1/2CC (45)
Cis-Diamminedichloroplatinum Ii
Penile Cancer
National Cancer Institute (NCI)P1CC (43)
Elimusertib
Penile Cancer
National Cancer Institute (NCI)P1CC (43)
scg142 tcr-t cells
Penile Cancer
The Affiliated Hospital of Qingdao UniversityP1CC (43)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Penile Cancer
National Cancer Institute (NCI)P1/2CC (42)
99mTc-nanoscan
Penile Cancer
The Netherlands Cancer InstituteN/AD (30)
Icg-99Mtc-Nanoscan
Penile Cancer
The Netherlands Cancer InstituteN/AD (30)